Who Should Not Take the Wegovy Pill?
Most writing about the Wegovy pill focuses on who it can help — if you're new to how it works, our overview guide is a good place to start. This guide does the opposite, and it matters just as much: setting out clearly who shouldn't take it, who needs extra caution, and why those lines exist.
The Wegovy pill (oral semaglutide) is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and for anyone with a known hypersensitivity to semaglutide or any of its ingredients. It isn't recommended during pregnancy, while trying to conceive, or while breastfeeding. A personal history of pancreatitis, significant gallbladder disease, or diabetic eye disease requires careful individual assessment rather than an automatic exclusion. It also shouldn't be combined with another GLP-1 medicine, and isn't licensed for type 1 diabetes. An honest, complete medical history at your consultation is the best way to ensure this treatment — or a suitable alternative — is right for you.
Medicines That Need Extra Consideration
Beyond the health conditions above, certain medicines require careful review when starting the Wegovy pill, since semaglutide slows how quickly your stomach empties, which can affect the absorption timing of other oral medicines taken around the same time.
- Insulin or sulfonylureas (such as glipizide, glimepiride or glyburide) — combined use increases hypoglycaemia risk and may require a dose adjustment
- Oral hormonal contraceptives — absorption can be reduced, particularly around dose changes
- Other medicines with a narrow therapeutic window, where even small changes in absorption timing could matter — your prescriber will review your full medication list for anything relevant
This is exactly why a complete, honest medication list — including anything over-the-counter or herbal — matters just as much as your medical history during your consultation.
Who Should Not Take the Wegovy Pill: Absolute Exclusions
A small number of situations mean the Wegovy pill shouldn't be prescribed at all, based on the UK licensing.
| Situation | Why |
|---|---|
| Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 | Contraindicated — reflects findings in animal studies regarding thyroid C-cell tumours |
| Known hypersensitivity to semaglutide or any excipient | Contraindicated — risk of serious allergic reaction including anaphylaxis and angioedema |
| Already taking another GLP-1 receptor agonist | Not recommended — combining GLP-1 medicines increases side-effect risk without established benefit |
| Type 1 diabetes | Not licensed for this condition — the Wegovy pill's mechanism and evidence base relate to weight management and type 2 diabetes |
Pregnancy, Trying to Conceive and Breastfeeding
The Wegovy pill isn't recommended during pregnancy, while actively trying to conceive, or while breastfeeding. This isn't simply bureaucratic caution: animal studies raised concerns about effects on fetal development, weight loss itself isn't advised during pregnancy regardless of the method, and the kind of human safety data that would be needed to properly assess risk during pregnancy doesn't exist and, for ethical reasons, never will be gathered through a controlled trial. If you're currently taking the Wegovy pill and become pregnant, or are actively planning a pregnancy, stop treatment and contact your prescriber promptly.
Because the Wegovy pill can also reduce how well oral hormonal contraceptives work, particularly around dose changes, effective contraception planning is a genuinely important conversation to have at your consultation if pregnancy isn't part of your current plans — not just if it is.
Conditions That Need Careful Individual Assessment
History of Pancreatitis
Semaglutide hasn't been specifically studied in people with a prior history of pancreatitis, so it's used with caution in this group. Acute pancreatitis, including rare but serious cases, has been reported in people taking GLP-1 receptor agonists more broadly. Anyone taking the Wegovy pill should be aware of the symptoms — persistent, severe abdominal pain, sometimes spreading to the back — and seek immediate medical attention if they occur. If pancreatitis is confirmed, treatment should not be restarted.
Gallbladder Disease
Gallstones and gallbladder inflammation have been reported in clinical trials, particularly linked to rapid weight loss rather than a direct drug effect. New upper-abdominal pain or jaundice (yellowing of the skin or eyes) should be reported to your prescriber promptly.
Diabetic Retinopathy
If you have a history of diabetic eye disease, the Wegovy pill can be used with caution, but rapid improvement in blood sugar control has been associated with temporary worsening of diabetic retinopathy in some cases. Your prescriber will want to monitor for any changes.
Kidney Function and Dehydration Risk
Severe vomiting or diarrhoea — both possible gastrointestinal side effects — can lead to dehydration, and there have been reports of acute kidney injury linked to this pathway, particularly during dose initiation and escalation. Maintaining good fluid intake and seeking advice if you notice reduced urination or dizziness is genuinely important, especially if you're prone to these side effects.
A Newer Consideration: Eye Health (NAION)
More recent data has flagged a possible association between GLP-1 receptor agonists and a rare eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION), which can cause sudden vision changes. This is still an area of ongoing monitoring rather than a settled, well-established risk, but anyone with pre-existing eye conditions should raise this with their prescriber, and anyone taking the Wegovy pill should seek urgent medical attention for any sudden vision changes.
People at Risk of Hypoglycaemia
The Wegovy pill can lower blood sugar, and this risk increases meaningfully if you're also taking insulin or an insulin secretagogue (a class of diabetes medicine including sulfonylureas). If you take either of these, your prescriber may need to adjust their dose alongside starting the Wegovy pill, and you should be educated on the signs and symptoms of hypoglycaemia — shakiness, sweating, confusion — before starting treatment.
Always disclose your complete medical history, current medications and any supplements during your consultation, even details that feel unrelated. This isn't a formality — several of the situations above (pancreatitis history, gallbladder disease, eye conditions) require individual clinical judgement rather than a simple yes or no, and your prescriber can only make that judgement with complete information.
People Who Aren't Clinically Eligible in the First Place
Beyond the specific medical exclusions above, the Wegovy pill is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related condition. People already at a healthy weight aren't eligible — this is a licensed medical treatment for a defined clinical population, not a cosmetic weight-management tool for anyone who wants to lose a small amount of weight. Age also matters: the Wegovy pill is licensed for adults, not for use in children or adolescents.
If One of These Applies to You
None of the situations above necessarily mean weight-loss treatment is entirely off the table — they mean the Wegovy pill specifically needs careful individual consideration, or that a different treatment altogether might be more appropriate. Mounjaro and the Wegovy injection have their own distinct eligibility profiles, and a proper consultation is designed to find the right option for your specific circumstances, not to fit you into a single predetermined product.
Why These Boundaries Exist
It's worth understanding that these exclusions and cautions aren't arbitrary bureaucracy — they reflect where the clinical evidence is genuinely strongest and safest. Some of the conditions above simply weren't well represented in the OASIS trial programme that underpins the Wegovy pill's licensing, which means there isn't robust safety data to confirm how the medicine behaves in those specific circumstances. Rather than guessing, careful individual assessment — or in some cases, a different treatment altogether — protects you from being prescribed something without the evidence base to support it being both safe and effective for your particular situation. An honest conversation at your consultation is what makes that assessment possible.
Frequently Asked Questions
If you or a family member have a history of medullary thyroid carcinoma, or you have Multiple Endocrine Neoplasia syndrome type 2, the Wegovy pill is contraindicated. This is a precaution shared across the GLP-1 medicine class.
No. It isn't recommended during pregnancy, while trying to conceive, or while breastfeeding. If you become pregnant while taking it, stop and contact your prescriber.
No. It shouldn't be combined with another GLP-1 receptor agonist medicine. If you're switching between treatments, this should always be planned with your prescriber.
No, it isn't licensed for type 1 diabetes. Its evidence base and licensed indications relate to weight management and type 2 diabetes specifically.
This isn't an automatic exclusion, but it needs careful individual discussion with your prescriber, since semaglutide hasn't been specifically studied in this group and pancreatitis has been reported with GLP-1 medicines more broadly.
Gallbladder disease requires individual assessment. Gallstones and gallbladder inflammation have been reported, particularly linked to rapid weight loss, so this is worth discussing at your consultation.
Yes, it can reduce how well oral contraceptives work, particularly around dose changes. Discuss contraceptive planning with your prescriber if this applies to you.
It's licensed for adults. It isn't intended for use in children or adolescents.
Persistent severe abdominal pain (possibly spreading to the back), signs of a severe allergic reaction, new upper-abdominal pain or jaundice, or sudden vision changes should all prompt seeking medical attention promptly.
Yes — Mounjaro and the Wegovy injection have their own eligibility profiles and may be more suitable depending on your specific situation. A consultation can help identify the right option for you.
Prescribing guidance is periodically updated as more real-world safety data becomes available, so it's possible some cautions may be refined in future. Always rely on your prescriber's current assessment rather than assuming today's guidance is permanently fixed.
Find Out If the Wegovy Pill Is Right For You
Start Your Free Online Consultation → Use code SWITCH10 if you're switching from another provider Happy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot- Wegovy® 25mg tablets, UK Summary of Product Characteristics, medicines.org.uk (emc).
- Novo Nordisk. Wegovy® Indications & HCP Information, novomedlink.com.
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087.
- MHRA. Approval of oral semaglutide (Wegovy pill), 11 June 2026.
This guide is for general information only and does not replace individual clinical advice. Always consult your prescriber about your specific circumstances, medicines and medical history before making decisions about treatment.